金城医药(300233) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥739,470,118.84, a decrease of 7.61% compared to the same period last year[8] - Net profit attributable to shareholders was ¥39,423,509.54, an increase of 44.23% year-on-year[8] - The net profit excluding non-recurring gains and losses was ¥34,215,800.49, up 102.90% compared to the previous year[8] - Basic earnings per share for the period was ¥0.10, representing a 42.86% increase year-on-year[8] - Total operating revenue for the current period reached ¥2,591,255,169.47, an increase from ¥2,095,524,809.86 in the previous period, representing a growth of approximately 23.7%[35] - Net profit for the period reached 267,089,226.39, a significant increase from 129,756,225.21 in the previous period, representing a growth of approximately 106.5%[38] - Operating profit increased to 338,944,390.07 from 173,269,596.37, reflecting a growth of about 95.7%[38] - Basic earnings per share rose to 0.67 from 0.31, marking an increase of 116.1%[40] - The company reported a total comprehensive income of 267,089,226.39, compared to 134,999,223.02 in the previous period, showing an increase of about 97.6%[40] Assets and Liabilities - Total assets at the end of the reporting period reached ¥5,674,992,548.08, a 7.58% increase from the end of the previous year[8] - The company's total assets increased to ¥5,674,992,548.08 from ¥5,275,153,179.53, reflecting a growth of approximately 7.6%[31] - Current assets totaled ¥2,172,293,095.83, slightly up from ¥2,139,270,567.35, showing a marginal increase of about 1.6%[31] - Non-current assets rose to ¥3,502,699,452.25 from ¥3,135,882,612.18, marking an increase of approximately 11.7%[31] - The total liabilities increased to ¥2,020,062,334.69 from ¥1,835,731,359.76, which is an increase of about 10.1%[34] - The company's equity attributable to shareholders reached ¥3,607,256,546.17, up from ¥3,394,465,354.19, indicating a growth of approximately 6.3%[34] Cash Flow - Cash flow from investing activities showed a net outflow of ¥348,083,859.42, a significant increase of 440.50% compared to the previous period[18] - The company reported a net cash inflow from financing activities of ¥99,140,461.81, a 225.74% increase year-on-year, mainly due to increased bank borrowings[18] - Cash flow from operating activities generated a net amount of 208,227,671.15, down from 232,213,332.77 in the previous period, a decrease of approximately 10.3%[44] - Cash and cash equivalents decreased from ¥981,084,481.31 to ¥889,390,294.90, a decline of about 9.3%[31] - Cash and cash equivalents at the end of the period were 843,296,253.96, down from 964,698,230.63, a decrease of approximately 12.5%[47] - Investment activities resulted in a net cash outflow of -348,083,859.42, compared to -64,400,662.19 in the previous period, reflecting a larger outflow[44] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,131[19] - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.28% of the shares, totaling 78,552,154 shares, with 18,829,799 shares pledged[22] - The second largest shareholder, Industrial and Commercial Bank of China - Guangfa Stable Growth Securities Investment Fund, holds 3.67% of the shares, totaling 14,200,000 shares[22] - The third largest shareholder, National Social Security Fund Combination One, holds 3.59% of the shares, totaling 13,900,000 shares[22] - Shareholder Peng Guohua holds 2.90% of the shares, totaling 11,220,000 shares[22] - Shareholder Zhao Hongfu holds 2.50% of the shares, totaling 9,676,000 shares, with 7,257,000 shares under lock-up[22] - Shareholder Zhao Yeqing holds 1.87% of the shares, totaling 7,227,500 shares, with 5,420,625 shares under lock-up[22] - Shareholder Fu Miaoqing holds 1.58% of the shares, totaling 6,138,332 shares, with 4,626,249 shares under lock-up[22] - The total number of restricted shares at the beginning of the period was 26,115,424, with 32,500 shares released during the period[25] Inventory and Operating Costs - The company's inventory increased by 39.89% to ¥547,416,758.01, attributed to increased stocking and rising raw material prices[12] - Operating costs rose by 43.01% to ¥1,377,627,180.93, primarily due to increased sales volume and raw material costs[15] - Total operating costs amounted to ¥2,283,411,856.62, up from ¥1,971,667,778.59, indicating an increase of about 15.8%[35] - Inventory increased significantly from ¥391,322,226.99 to ¥547,416,758.01, representing a growth of approximately 40%[31] Future Outlook - The company has not disclosed any new strategies or future outlook in the provided documents[26] - The company reported a net profit margin improvement, with net income figures to be detailed in future reports[35]